Treatment With Etranacogene Dezaparvovec in a Renal Transplant Recipient With Hemophilia B on Concomitant Systemic Immunosuppressive Therapy

M.Y.L reports receiving honorarium for participation in advisory boards for Sanofi, Hema Biologics and SeraGene. G.M.R is a consultant for Grifols. Other authors declare no competing financial interests. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.